Literature DB >> 18376130

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.

Dan Granberg1, Hans Jacobsson, Kjell Oberg, Jörgen Gustavsson, Mikael Lehtihet.   

Abstract

Gastrinomas may occur in the pancreas, duodenum or peripancreatic lymph nodes. The gastrin overproduction leads to the Zollinger-Ellison syndrome with multiple gastric and duodenal ulcers and diarrhea. About two thirds of gastrinomas are malignant. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery should always be considered if the liver is not involved. Proton pump inhibitors offer symptomatic relief. Medical therapy for tumor control includes biotherapy with alpha-interferon and somatostatin analogs yielding a response rate of about 10-15%, chemotherapy or targeted radiotherapy. We describe a patient with almost complete response on treatment with Sandostatin LAR, a long-acting somatostatin analog. In patients with metastatic gastrinomas not suitable for chemotherapy, interferon or targeted radiotherapy, single therapy with somatostatin analogs may be an alternative. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376130     DOI: 10.1159/000122229

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.

Authors:  A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

2.  Cancer: antitumor effects of octreotide LAR, a somatostatin analog.

Authors:  Kjell Oberg
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

Review 3.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

Review 4.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

Review 5.  The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Authors:  Valentina Guarnotta; Chiara Martini; Maria Vittoria Davì; Genoveffa Pizza; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.